Jaguar Health’s Napo reports initial PoC results from trial of crofelemer

Jaguar Health’s (JAGX) Napo Pharmaceuticals and Napo Therapeuticsy announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support in patients with intestinal failure due to microvillus inclusion disease and short bowel syndrome by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption. These initial results were recently presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who serves as the Chief of Pediatric Gastroenterology, Hepatology and Nutrition at Sheikh Khalifa Medical City in Abu Dhabi in the United Arab Emirates. He is the Principal Investigator for this ongoing exploratory, single-arm open label non-randomized investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders, including MVID and SBS-IF. The investigator-initiated trial in Abu Dhabi is evaluating the safety and effectiveness of crofelemer in pediatric patients with intestinal failure and includes an assessment of crofelemer’s potential to be safely administered to patients with intestinal failure from MVID, SBS, and other congenital diarrheal disorders in optimum dose levels for the patients.